Ongoing clinical trials explore the diagnostic potential of HSP70 for the isolation of circulating tumor cells (ClinicalTrials.gov Identifier: NCT04628806) and in prevention where HSP70 DNA is a component of a dual vaccine for the treatment of lesions with increased risk of cervical cancer (ClinicalTrials.gov Identifier: NCT03911076). The gene discussed is HSPA1A; the disease is cervical carcinoma.